MICHAYALA BUSH: Open Payments
NPI 1396288684 · SMITHVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 42 payments from 10 companies in 2025. Trend: 2023 $289 · 2024 $244 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $249 |
| Neurocrine BioSciences, Inc. | 9 | $232 |
| E.R. Squibb & Sons, L.L.C. | 8 | $171 |
| Alkermes, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Lundbeck LLC | 1 | $25 |
| ABBVIE INC. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
Products named: FANAPT, INGREZZA, COBENFY, ARISTADA, ABILIFY MAINTENA, INVEGA SUSTENNA, Qelbree, ABILIFY ASIMTUFII.
Industry payments across GA — which companies pay providers there.
